Kenya begins nationwide rollout of long-acting HIV prevention drug
Kenya takes a massive leap in HIV prevention, here is everything you need to know about the Lenacapavir rollout...
✨ Key Highlights
Kenya has officially launched the nationwide rollout of Lenacapavir (LEN), a new long-acting injectable drug for HIV prevention, on Thursday, February 27, 2026. This significant advancement offers a more convenient option alongside existing oral and injectable PrEP methods.
- The drug, administered once every six months, demonstrated up to 100 percent efficacy in clinical trials for women.
- The rollout is managed by the Ministry of Health through the National Aids and STIs Control Programme (Nascop).
- Clients must undergo a mandatory HIV test, weight screening, and disclose current medications (like TB drugs) to ensure eligibility and prevent drug resistance.
Continue Reading
Read the complete article from Nation News
Part of the Day's Coverage
Kenya Begins Nationwide Rollout of Long-Acting HIV Prevention Drug - February 2026
Kenya has officially launched the nationwide rollout of Lenacapavir (LEN), a new long-acting injectable drug for HIV prevention, on Thursday, February 27, 2026. This significant advancement offers a more convenient option alongside existing oral and injectable PrEP methods. Kenya is also seeking to enhance its digital health infrastructure and reduce maternal deaths by partnering with the World Bank, a key focus for President William Ruto's administration. Separately, AMPATH Kenya has launched a new national breast cancer care initiative aimed at improving access to high-quality treatment and reducing the disease's burden across the country.
